Association of DR4 (TRAIL-R1) Polymorphisms with Cancer Risk in Caucasians: an Updated Meta-analysis

Chen, Wei; Tang, Wenru; Zhang, Ming; Chang, Kwen-Jen; Wei, Yun-Lin

doi:10.7314/apjcp.2014.15.6.2889

Cited by 4 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No predictions of the effects of this SNP on protein function were identified by SIFT or PolyPhen-2. While studies of the associations between TNFRSF10A rs17620 and fatigue were not found, TRAIL polymorphisms are associated with increased cancer risk [135, 136]. In our study, patients who were heterozygous or homozygous for the rare C allele were predicted to have a steeper trajectory of morning fatigue scores that suggests clinically meaningful increases in fatigue at four of the six assessments (i.e., assessments 2, 4, 5 and 6) (Figure 3A).…”

Section: Discussionmentioning

confidence: 53%

Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy

et al. 2017

View full text Add to dashboard Cite

Fatigue, a highly prevalent and distressing symptom during chemotherapy (CTX), demonstrates diurnal and interindividual variability in severity. Little is known about the associations between variations in genes involved in inflammatory processes and morning and evening fatigue severity during CTX. The purposes of this study, in a sample of oncology patients (N=543) with breast, gastrointestinal (GI), gynecological (GYN), or lung cancer who received two cycles of CTX, were to determine whether variations in genes involved in inflammatory processes were associated with inter-individual variability in initial levels as well as in the trajectories of morning and evening fatigue. Patients completed the Lee Fatigue Scale to determine morning and evening fatigue severity a total of six times over two cycles of CTX. Using a whole exome array, 309 single nucleotide polymorphisms among the 64 candidate genes that passed all quality control filters were evaluated using hierarchical linear modeling (HLM). Based on the results of the HLM analyses, the final SNPs were evaluated for their potential impact on protein function using two bioinformational tools. The following inflammatory pathways were represented: chemokines (3 genes); cytokines (12 genes); inflammasome (11 genes); Janus kinase/signal transducers and activators of transcription (JAK/STAT, 10 genes); mitogen-activated protein kinase/jun amino-terminal kinases (MAPK/JNK, 3 genes); nuclear factor-kappa beta (NFkB, 18 genes); and NFkB and MAP/JNK (7 genes). After controlling for self-reported and genomic estimates of race and ethnicity, polymorphisms in six genes from the cytokine (2 genes); inflammasome (2 genes); and NFkB (2 genes) pathways were associated with both morning and evening fatigue. Polymorphisms in six genes from the inflammasome (1 gene); JAK/STAT (1 gene); and NFkB (4 genes) pathways were associated with only morning fatigue. Polymorphisms in three genes from the inflammasome (2 genes) and the NFkB (1 gene) pathways were associated with only evening fatigue. Taken together, these findings add to the growing body of evidence that suggests that morning and evening fatigue are distinct symptoms.

show abstract

Section: Discussionmentioning

confidence: 53%

Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The C-G single nucleotide polymorphism in exon 4 of DR4 gene is the most studied polymorphism which has recently been linked with cancer in Caucasian susceptibility (Chen et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

“…They reported that there was no association between C626G polymorphism and the risk of cancer in all genetic models when all the eligible studies were pooled into the metaanalysis (Chen et al, 2009). But, in a recent meta-analysis, it has been reported that TRAIL DR4 C626G and A683C polymorphisms were indeed associated with cancer risk (Chen et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Association between Laryngeal Squamous Cell Carcinoma and Polymorphisms in Tumor Necrosis Factor Related Apoptosis Induce Ligand (TRAIL), TRAIL Receptor and sTRAIL Levels

Verim¹,

Turan²,

Farooqı³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The laryngeal squamous cell carcinoma (LSCC) is one of the most common malignant tumors occurring in the head and neck. Tumor necrosis factor related apoptosis induce ligand (TRAIL) and TRAIL-receptors (DR4, DR5, DcR1, DcR2) are known as important members of TRAIL-mediated biochemical signaling pathway. Associations between polymorphisms in these genes and clinicopathological characteristics of human laryngeal carcinoma are not well defined. This study therefore aimed to investigate a possible relationship among the TRAIL and TRAIL-DR4 polymorphisms and sTRAIL levels in the risk or progression of LSCC. A total of 99 patients with laryngeal cancer and 120 healthy subjects were enrolled in the study. DR4 C626G and TRAIL 1595 C/T genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis and sTRAIL levels were measured by ELISA. There were significant differences in the distribution of DR4 C626G genotypes and frequencies of the alleles between laryngeal cancer patients and controls (p<0.001) but not in TRAIL 1595 C/T. We found the increased frequency of the DR4 C626G homozygote CC genotype in patients than in controls (p<0.001). Haplotype analysis revealed that there was also a statistically significant relationship between TRAIL and TRAIL-DR4 polymorphisms and laryngeal cancer. Serum sTRAIL levels in the laryngeal patients with CC genotype who had advanced tumour stage were lower than those of patients with early tumor stage (p=0.014). Our findings suggest that DR4 C626G genotypes and sTRAIL levels might be associated with progression of laryngeal cancer in the Turkish population.

show abstract

“…The DR4 gene is highly polymorphic. The trio ‐C626G, ‐A683C, and ‐A1322G polymorphisms of TRAIL‐R1 gene were previously studied in different cancers; however, few reports are available for HCC especially in Arab‐African nations. DR4‐C626G polymorphism occurs in the ectodomain region of DR4, whereas the DR4‐A683C and DR4‐A1322G polymorphisms occur in the extracellular cysteine‐rich domain and DD region of DR4, respectively.…”

Section: Introductionmentioning

confidence: 99%

“…As for DR4‐A1322G polymorphism, it is an adenine to guanine transition at nucleotide 1322 that results in the conversion of lysine into arginine. These genetic variants may lead to alterations in the TRAIL‐binding domain and, thus, alter DR4 affinity for TRAIL …”

Section: Introductionmentioning

confidence: 99%

Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma

Zayed

Zahran

Khorshied

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, particularly in Egypt. The role of apoptosis in tumorigenesis has been welldocumented and resistance to apoptosis is a hallmark of cancer. Several studies discussed the association between death receptor 4 (DR4) genetic variants and HCC risk. Aim:To study the possible link between DR4 gene polymorphisms and the susceptibility to HCC.Methods: Genotyping of DR4-C626G, -A683C, and DR4-A1322G single nucleotide polymorphisms (SNP) was determined by polymerase chain reaction assay for 100 de novo HCV-related HCC patients, 100 chronic hepatitis C-related liver cirrhosis patients, and 150 healthy controls.Results: DR4-A1322G polymorphic genotypes (AG and GG) were significantly higher in HCC and cirrhotic patients than controls. The AG genotype conferred two-fold increased risk of HCC (odds ratio [OR], 2.34; 95% confidence interval [CI], 1.56-3.51) and the risk increased to three-fold for the GG genotype (OR, 3.51; 95%CI, 2.33-5.28). The frequency of DR4-C626G and -A683C SNPs in HCC and cirrhotic patients were not significantly different from the controls. Combined genotype analysis showed that coinheritance of the polymorphic genotypes of DR4-C626G and -A1322G conferred nine-fold increased risk of HCC (OR, 9.34; 95%CI,.The risk increased to be 12-fold when DR4-A683C and -A1322G variants were coinherited (OR, 11.9; 95%CI,). Coexistence of the variant genotypes of the three SNPs conferred almost 10-fold increased risk of HCC (OR, 9.75; 95%CI,. Conclusions:The G allele of DR4 -A1322G could be considered as a novel independent molecular predictor for HCV-related HCC in the Egyptian population.

show abstract

Association of DR4 (TRAIL-R1) Polymorphisms with Cancer Risk in Caucasians: an Updated Meta-analysis

Cited by 4 publications

References 25 publications

Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy

Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy

Association between Laryngeal Squamous Cell Carcinoma and Polymorphisms in Tumor Necrosis Factor Related Apoptosis Induce Ligand (TRAIL), TRAIL Receptor and sTRAIL Levels

Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma

Contact Info

Product

Resources

About